DeCure for Male reproductive system disease

Male infertility accounts for roughly half of all infertility cases. A 2020 clinical guideline from the AUA and ASRM, based on literature from 2000 to 2019, states that male contributions to infertility are prevalent and that specific treatments plus assisted reproductive techniques are effective at managing the condition. The guideline covers medical therapies, surgical techniques, and use of intrauterine insemination, in vitro fertilisation, and intracytoplasmic sperm injection. A 2010 review notes that men with impaired reproductive potential often benefit from directed medical therapy targeting endocrine anomalies, infection or inflammation, ejaculatory dysfunction, and erectile dysfunction. A 2022 review, however, states that currently available treatments are prohibitively expensive, difficult to obtain, require lengthy courses, and have many side effects; it suggests herbal therapy as a less expensive alternative with fewer side effects, but provides no clinical trial data or response rates.

The male reproductive system maintains an immunoprivileged environment to protect germ cells, but can be infected by microorganisms via haematogenous or ascending routes. A 2021 chapter describes how tissue-specific cells in the male system are equipped with pattern recognition receptors and negative regulatory systems; unrestrictive innate immune responses can disrupt immune homeostasis and lead to inflammatory conditions, which are an important cause of male infertility. A 2002 theoretical model proposes that sexually transmitted pathogens in the ejaculate trigger immune activity in the female reproductive tract, which may also attack spermatozoa, thereby setting up competition among sperm from different males to overcome those defences.

A 2023 book claims to cover recent advances in the male reproductive system, including physiological structure, function, aetiology, molecular mechanisms of common diseases, and evaluation and treatment, but provides no specific data or results. The 2020 guideline will undergo additional literature reviews and updating as knowledge expands.

What is still missing are large, well-funded randomised controlled trials comparing specific treatments—including herbal remedies—against placebo or standard care, with clearly defined outcomes such as live birth rates. Patient stratification by aetiology (e.g., infection, endocrine, genetic) is rarely performed in existing studies, and no single trial has sufficient power to guide individualised therapy. The cost and accessibility barriers noted in the 2022 review remain unaddressed by any published efficacy data.